World J Oncol

World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access

Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc

Journal website http://www.wjon.org

Original Article

Volume 6, Number 1, February 2015, pages 276-282

Treatment Approaches in 102 Elderly Patients With Non-Small Cell Lung Cancer

**Table 1.** Patient Characteristics
Characteristics	No treatment group, n (%)	Treatment group, n (%)	P value	Total, n (%)
Median age (min - max)	78 (75 - 85)	76 (75 - 85)	0.36	77 (75 - 85)
Gender			0.41
Male	53 (94.6)	45 (97.8)		98 (96.1)
Female	3 (5.4)	1 (2.2)		4 (3.9)
Age			0.42
< 80	36 (64.3)	33 (71.7)		69 (67.6)
> 80	20 (35.7)	13 (28.3)		33 (32.4)
Surgery			0.53
None	55 (98.2)	44 (95.6)		99 (97)
Lobectomy	1 (1.8)	1 (2.2)		2 (2)
Pneumonectomy	0	1 (2.2)		1 (1)
Histological type
Adenocancer	15 (26.8)	5 (10.8)	0.048	20 (19.6)
Squamous cancer	27 (48.2)	31 (67.4)		58 (56.9)
Unknown	14 (25)	10 (21.8)		24 (23.5)
Hemoglobin in diagnosis
< 10	19 (33.9)	7 (15.2)	0.003	26 (25.5)
> 10	37 (66.1)	39 (84.8)		76 (74.5)
Baseline co-morbidities
Hypertension	13 (23.2)	13 (28.3)	0.005	26 (25.5)
Cardiac co-morbidities	14 (25)	11 (23.9)		25 (24.5)
Pulmonary co-morbidities	6 (10.7)	4 (8.7)		10 (9.8)
Diabetes mellitus	2 (3.6)	10 (21.8)		12 (11.8)
≥ 3 co-morbidities	15 (26.8)	2 (4.3)		17 (16.7)
ECOG performance status
0	2 (3.6)	3 (6.5)	< 0.001	5 (4.9)
1	4 (7.2)	21 (45.6)		25 (24.5)
2	13 (23.2)	13 (28.3)		26 (25.5)
≥ 3	37 (66)	9 (19.6)		46 (45.1)
Stage
1	0	2 (4.3)	< 0.001	2 (2)
2	1 (1.8)	0		1 (1)
3A	3 (5.4)	8 (17.4)		11 (10.8)
3B	10 (17.8)	21 (45.6)		31 (30.4)
4	42 (75)	15 (32.7)		57 (55.8)
Metastasis site
Brain	6 (10.7)	2 (4.3)	0.003	8 (14)
Adrenal glands	1 (1.8)	1 (2.2)		2 (3.5)
Bone	4 (7.2)	5 (10.9)		9 (15.8)
Contralateral lung	10 (17.8)	3 (6.5)		13 (22.8)
Multiple metastasis	21 (37.5)	4 (8.7)		25 (43.9)
Treated with chemotherapy
Metastatic disease	N	N		15 (26.3)
Locally advanced disease				12 (26.6)
No				73 (71.6)
Treated with radiotherapy
Radiotherapy	N	N		25 (55.6)
Chemoradiotherapy				5 (11.1)
Palliative radiotherapy				39 (68.2)

Table 1. Patient Characteristics

Characteristics

No treatment group, n (%)

Treatment group, n (%)

P value

Total, n (%)

Median age (min - max)

78 (75 - 85)

76 (75 - 85)

0.36

77 (75 - 85)

Gender

0.41

Male

53 (94.6)

45 (97.8)

98 (96.1)

Female

3 (5.4)

1 (2.2)

4 (3.9)

Age

0.42

< 80

36 (64.3)

33 (71.7)

69 (67.6)

> 80

20 (35.7)

13 (28.3)

33 (32.4)

Surgery

0.53

None

55 (98.2)

44 (95.6)

99 (97)

Lobectomy

1 (1.8)

1 (2.2)

2 (2)

Pneumonectomy

1 (2.2)

1 (1)

Histological type

Adenocancer

15 (26.8)

5 (10.8)

0.048

20 (19.6)

Squamous cancer

27 (48.2)

31 (67.4)

58 (56.9)

Unknown

14 (25)

10 (21.8)

24 (23.5)

Hemoglobin in diagnosis

< 10

19 (33.9)

7 (15.2)

0.003

26 (25.5)

> 10

37 (66.1)

39 (84.8)

76 (74.5)

Baseline co-morbidities

Hypertension

13 (23.2)

13 (28.3)

0.005

26 (25.5)

Cardiac co-morbidities

14 (25)

11 (23.9)

25 (24.5)

Pulmonary co-morbidities

6 (10.7)

4 (8.7)

10 (9.8)

Diabetes mellitus

2 (3.6)

10 (21.8)

12 (11.8)

≥ 3 co-morbidities

15 (26.8)

2 (4.3)

17 (16.7)

ECOG performance status

2 (3.6)

3 (6.5)

< 0.001

5 (4.9)

4 (7.2)

21 (45.6)

25 (24.5)

13 (23.2)

13 (28.3)

26 (25.5)

≥ 3

37 (66)

9 (19.6)

46 (45.1)

Stage

2 (4.3)

< 0.001

2 (2)

1 (1.8)

1 (1)

3 (5.4)

8 (17.4)

11 (10.8)

10 (17.8)

21 (45.6)

31 (30.4)

42 (75)

15 (32.7)

57 (55.8)

Metastasis site

Brain

6 (10.7)

2 (4.3)

0.003

8 (14)

Adrenal glands

1 (1.8)

1 (2.2)

2 (3.5)

Bone

4 (7.2)

5 (10.9)

9 (15.8)

Contralateral lung

10 (17.8)

3 (6.5)

13 (22.8)

Multiple metastasis

21 (37.5)

4 (8.7)

25 (43.9)

Treated with chemotherapy

Metastatic disease

15 (26.3)

Locally advanced disease

12 (26.6)

73 (71.6)

Treated with radiotherapy

Radiotherapy

25 (55.6)

Chemoradiotherapy

5 (11.1)

Palliative radiotherapy

39 (68.2)

**Table 2.** Chemotherapy Regimens Used in Metastatic and Non-Metastatic Setting
Chemotherapy regimens	Number of patients, n (%)	Explanation
Gemcitabine/cisplatin	2 (16.7)	6 (40)	Gemcitabine 1,000 mg/m² day 1 and 8; cisplatin 60 mg/m² day 1 every 21 days
Docetaxel/cisplatin	1 (8.3)	3 (20)	Docetaxel 60 mg/m² day 1; cisplatin 60 mg/m² day 1 every 21 days
Gemcitabine/carboplatin	2 (16.7)	1 (6.7)	Gemcitabine 1,000 mg/m² day 1 and 8; carboplatin AUC 4 day 1 every 21 days
Docetaxel/carboplatin	1 (8.3)	2 (13.3)	Docetaxel 60 mg/m² day 1; carboplatin AUC 4 day 1 every 21 days
Vinorelbine/cisplatin	1 (8.3)	2 (13.3)	Vinorelbine 25 mg/m² day 1 and 8; cisplatin 60 mg/m² day 1 every 21 days
Vinorelbine	1 (8.3)	1 (6.7)	Vinorelbine 25 mg/m² IV first day and 60 - 80 mg/m² oral day 1 and 8 every 21 days
Gemcitabine	1 (8.3)	No	Gemcitabine 1,200 mg/m² days 1 and 8 every 21 days
Cisplatin/etoposide	3 (25)	No	Cisplatin 60 mg/m² day 1; etoposide 100 mg/m² days 1, 2 and 3 every 21 days

Table 2. Chemotherapy Regimens Used in Metastatic and Non-Metastatic Setting

Chemotherapy regimens

Number of patients, n (%)

Explanation

Non-metastatic

Metastatic

Gemcitabine/cisplatin

2 (16.7)

6 (40)

Gemcitabine 1,000 mg/m² day 1 and 8; cisplatin 60 mg/m² day 1 every 21 days

Docetaxel/cisplatin

1 (8.3)

3 (20)

Docetaxel 60 mg/m² day 1; cisplatin 60 mg/m² day 1 every 21 days

Gemcitabine/carboplatin

2 (16.7)

1 (6.7)

Gemcitabine 1,000 mg/m² day 1 and 8; carboplatin AUC 4 day 1 every 21 days

Docetaxel/carboplatin

1 (8.3)

2 (13.3)

Docetaxel 60 mg/m² day 1; carboplatin AUC 4 day 1 every 21 days

Vinorelbine/cisplatin

1 (8.3)

2 (13.3)

Vinorelbine 25 mg/m² day 1 and 8; cisplatin 60 mg/m² day 1 every 21 days

Vinorelbine

1 (8.3)

1 (6.7)

Vinorelbine 25 mg/m² IV first day and 60 - 80 mg/m² oral day 1 and 8 every 21 days

Gemcitabine

1 (8.3)

Gemcitabine 1,200 mg/m² days 1 and 8 every 21 days

Cisplatin/etoposide

3 (25)

Cisplatin 60 mg/m² day 1; etoposide 100 mg/m² days 1, 2 and 3 every 21 days

**Table 3.** P values of Prognostic Factors
Factor	P value
Gender	0.802	0.635
Hemoglobin	0.903	< 0.001
Pathology	0.986	0.592
LVI	0.031	0.135
Perineural invasion	0.072	0.342
Stage	0.515	< 0.001
Metastatic site	0.032	< 0.001
Receiving chemotherapy	0.094	0.021
Receiving treatment	0.671	0.534

Table 3. P values of Prognostic Factors

Factor

P value

Progression-free survival

Overall survival

Gender

0.802

0.635

Hemoglobin

0.903

< 0.001

Pathology

0.986

0.592

LVI

0.031

0.135

Perineural invasion

0.072

0.342

Stage

0.515

< 0.001

Metastatic site

0.032

< 0.001

Receiving chemotherapy

0.094

0.021

Receiving treatment

0.671

0.534